Cryotherapy is Associated with Improved Clinical Outcomes of Sorafenib Therapy for Advanced Hepatocellular Carcinoma

Cell Biochemistry and Biophysics

Volumn 63, Issue 2, 2012, Pages 159-169

  Yang, Yongping ^a,b   Lu, Yinying ^a   Wang, Chunping ^a   Bai, Wenlin ^a   Qu, Jianhui ^a,b   Chen, Yan ^a   Chang, Xiujuan ^a   An, Linjing ^a   Zhou, Lin ^a   Zeng, Zhen ^a   Lou, Min ^a   Lv, Jiyun ^a  

^a BEIJING 302 HOSPITAL   (China)

^b Beijing Institute of Infectious Diseases   (China)

Author keywords

Cryotherapy; Efficacy; Hepatocellular carcinoma; Microvessel density; Safety; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; SORAFENIB;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MICROVASCULATURE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CRYOTHERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICROVESSELS; NEOPLASM STAGING; PYRIDINES; TREATMENT OUTCOME;

EID: 84861228215     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9353-2     Document Type: Article

References (38)

1. Parkin, D. M. (2001). Global cancer statistics in the year 2000. Lancet Oncology, 2, 533-543.
2. Zhaoyou, T. (2009). Perspective of clinical oncology from the viewpoint of liver cancer studies. Tumor (China), 29, 1-4.
3. Yoo, H. Y., Patt, C. H., Geschwind, J. F., et al. (2003). The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-Year survival has improved significantly with time. Journal of Clinical Oncology, 21, 4329-4335.
4. Yang, H. I., Lu, S. N., Liaw, Y. F., et al. (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma. The New England Journal of Medicine, 347, 168-174.
5. Sherman, M. (2005). Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Seminars in Liver Disease, 25, 143-154.
6. Llovet, J. M., Burroughs, A., & Bruix, J. (2003). Hepatocellular carcinoma. Lancet, 362, 1907-1917.
7. Llovet, J. M., Burroughs, A., & Bruix, J. (1999). Prognosis of hepatocellular carcinoma: The BCLC staging classification. Seminars in Liver Disease, 19, 329-338.
8. Bruix, J., & Llovet, J. M. (2002). Prognosis prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 35, 519-524.
9. Bruix, J., & Sherman, M. (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-1236.
10. Park, K. W., Park, J. W., et al. (2008). Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. Journal of Gastroenterology and Hepatology, 23, 467-473.
11. Llovet, J. M., Fuster, J., Bruix, J., & Barcelona-Clinic Liver Cancer Group. (2004). The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplantation, 10, S115-S120.
12. Cheng, A. L., Kang, Y. K., Chen, Z., et al. (2009). Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Lancet Oncology, 10, 25-34.
13. Llovet, J. M., Ricci, S., Mazzaferro, V., SHARP Investigators Study Group, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 359, 378-390.
14. Furuse, J. (2008). Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics, 2, 779-788.
15. Hakimé, A., Hines-Peralta, A., Peddi, H., et al. (2007). Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: Study in mice. Radiology, 244, 464-470.
16. Atwell, T. D., Farrell, M. A., Callstrom, M. R., et al. (2007). Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: Initial experience. Radiology, 243, 276-283.
17. Jungraithmayr, W., Burger, D., Olschewski, M., & Eggstein, S. (2005). Cryoablation of malignant liver tumor: Results of a single center study. Hepatobiliary & Pancreatic Diseases International, 4, 554-560.
18. Lencioni, R., & Llovet, J. M. (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in Liver Diseases, 30, 52-60.
19. Trotti, A., Colevas, A. D., Setser, A., et al. (2003). CTCAE v3. 0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13, 176-181.
20. Wang, C., Lu, Y., Chen, Y., et al. (2009). Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: A prospective study. Clinical Experimental Metastasis, 26, 839-848.
21. Kuang, D. M., Wu, Y., Chen, N., Cheng, J., Zhuang, S. M., & Zheng, L. (2007). Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood, 110, 587-595.
22. Poon, R. T., Ng, I. O., Lau, C., et al. (2002). Tumor microvessel density as a predictor recurrence after resection of hepatocellular carcinoma: A prospective study. Journal of Clinical Oncology, 20, 1775-1785.
23. Yau, T., Chan, P., Epstain, R., & Poon, R. T. P. (2009). Management of advanced hepatocellular carcinoma in era of target therapy. Liver International, 29, 10-17.
24. Yau, T., Chan, P., Ng, K. K., et al. (2009). Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response. Cancer, 115, 428-436.
25. Greten, T. F., Korangy, F., Manns, M. P., & Malek, N. P. (2009). Molecular therapy for the treatment of hepatocellular carcinoma. British Journal of Cancer, 100, 19-23.
26. Zuro, L. M., & Staren, E. D. (1996). Cryosurgical ablation of unresectable hepatic tumors. Association of perioperative Registered Nurses (AORN) Journal, 64, 231-236, 239-244.
27. Shimizu, T., Sakuhara, Y., Abo, D., et al. (2009). Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. Journal of Hepatobiliary & Pancreatic Surgery, 16, 816-823.
28. Osada, S., Imai, H., Tomita, H., et al. (2007). Serum cytokine levels in response to hepatic cryoablation. Journal of Surgical Oncology, 95, 491-498.
29. Shim, J. H., Park, J. W., Choi, J. I., Park, B. J., & Kim, C. M. (2009). Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. Journal of Cancer Research and Clinical Oncology, 135, 617-625.
30. Pinter, M., Sieghart, W., Ivo Graziadei, I., et al. (2009). Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. The Oncologist, 14, 70-76.
31. Kane, R. C., Farrell, A. T., Madabushi, R., et al. (2009). Sorafenib for the treatment of unresectable hepatocellular carcinoma. The Oncologist, 14, 95-100.
32. Cheng, B. Q., Jia, C. Q., Liu, C. T., et al. (2008). Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. Journal of the American Medical Association, 299, 1669-1677.
33. Furuse, J., Ishii, H., Nakachi, K., et al. (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Science, 99, 159-165.
34. Wörns, M. A., Weinmann, A., Pfingst, K., et al. (2009). Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Journal of Clinical Gastroenterology, 43, 489-495.
35. Vincenzi, B., Santini, D., Russo, A., et al. (2010). Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist, 15, 85-92.
36. Schramm, C., Schuch, G., & Lohse, A. W. (2008). Sorafenib-induced liver failure. American Journal of Gastroenterology, 103, 2162-2163.
37. Semela, D., & Dufour, J. F. (2004). Angiogenesis and hepatocellular carcinoma. Journal of Hepatology, 41, 864-880.
38. Liu, L., Cao, Y., Chen, C., et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research, 66, 11851-11858.